Latest Stories

Jefferies Says Supply-Chain Issues Larger Than Patents for Shots

Jefferies analyst Michael Yee wrote in a note that while Covid vaccine stocks slumped on headlines that the Biden administration may support a waiver of vaccine patents, the bottleneck is “neither access nor patents (or price) but simply that there aren’t enough vials, raw materials, etc. to manufacture it regardless of patents.”

View More

Coronavirus and Force Majeure Clauses

Covid-19 has legal teams exploring whether to turn to a rarely tested section of their contracts: the force majeure, or act of god, clause.

Up Next

Coronavirus Is Changing the Way Lawyers Work